Todd M. Pope

Venture Advisor

Todd serves as Partner at Revival Healthcare Capital, where he brings 30 years of technology, medical device, and leadership experience across large-cap and start-up medtech. His last 20 years have been in CEO roles in both private and public companies. Prior to joining RVLHC, Todd was the executive chairman and co-founder of UV Innovators. While at UV Innovators, Todd played an integral role in developing the world’s first handheld instant UVC surface disinfection device, bringing a powerful and portable hospital-grade solution to all environments.

Before UV Innovators, Todd was the President and CEO of TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with laparoscopic and robotic options in today's value-based healthcare environment.

Todd’s previous roles included Global President of Johnson & Johnson Cordis; where he led a multi-billion-dollar business unit comprised of 3 distinct companies; Cardiology, Neurovascular, and Peripheral Vascular. Todd has also held various executive positions, including Liquidia Technologies' CEO, a nanotechnology-based healthcare company, in Research Triangle Park, North Carolina.

Significant portions of Todd's career have been spent focused on healthcare customers across the globe. He served 14 years in various management roles at Johnson & Johnson's Ethicon Endo-Surgery Division and Boston Scientific, where he rose to Vice President, Global Sales, and Marketing, Neurovascular Division.

Todd serves on the Board of Directors of AdvaMed ACCEL where he is the current Chairman of the Board. He also serves on the Kenan-Flagler Board of Visitors and the Educational Foundation for the University of North Carolina at Chapel Hill, where he is the immediate past Executive Chairman of the Board. In addition to serving as Chairman of the Board of Directors of AdvaMed ACCEL, Todd is also on the board of directors of Distalmotion, a Revival portfolio company; Humacyte, a regenerative medicine company leveraging a scalable technology platform to develop bioengineered human tissues. He was named to TIME Magazine’s 2018 list of 50 Most Influential People in Health Care.